Locations:
Search IconSearch
October 22, 2018/Cancer/Research

Which Breast Reconstruction Technique Is Best for Patients Undergoing Post-Mastectomy Radiation Therapy?

10-year outcomes favor autologous over implant

rad-treatment_650x450

Radiation therapy and breast reconstruction after mastectomy don’t always go well together. Rates of infection, dehiscence, skin and/or flap necrosis, and hematoma are higher in patients that undergo reconstruction and have post-mastectomy radiation therapy. In those patients that have reconstruction with a tissue expander/implant (TE/I), radiation is associated with higher rates of implant extrusion, leak or capsular contracture, while those that have autologous reconstruction (AR) are at risk for hernias as well.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Toxicity profiles vary by technique and timing, and data currently available in the literature provide little guidance on determining the optimal treatment approach, says Chirag Shah, MD, Director of Clinical Research and Breast Radiation Oncology in Cleveland Clinic’s Department of Radiation Oncology.

In response, Dr. Shah and colleagues at Cleveland Clinic recently compared rates of complications in patients who had post-mastectomy radiation therapy both before and after AR or TE/I.

“We suspected that radiation to a TE/I, regardless of timing, would portend worse outcomes,” says Dr. Shah. “Our study confirmed this. For patients requiring radiation after mastectomy, AR was associated with fewer trips back to the operating room for complications and fewer reconstruction failures.”

Results of this study will be shared in an oral presentation at the 2018 ASTRO Annual Meeting in San Antonio.

Comparing techniques and timing

The study included 230 patients that had 233 breast reconstructions. The patients had either AR or TE/I, either before or after radiation therapy, between 2000 and 2008. Median follow-up was 7.6 years. Age, BMI, and rates of active smoking, diabetes and hypertension were similar among the groups. Reconstruction was performed at the time of mastectomy, before radiation therapy, in 81 percent of patients.

Overall, rates of reconstruction failure (resulting in converting to another reconstruction technique or a flat chest wall) and complications requiring re-operation were significantly higher with TE/I as compared to AR (Table).

Advertisement

Table listing rates of reconstruction failure and complications requiring re-operation.

On multivariate analysis, the most significant predictors of complications requiring re-operation were:

  • TE/I (Odds Ratio 2.4; P = 0.007).
  • BMI ≥ 30 (Odds Ratio 3.4; P = 0.002).
  • Active smoking (Odds Ratio 2.7; P = 0.002).

The only significant predictor of reconstruction failure was TE/I (Odds Ratio 5.4; P < 0.001).

However, the rate of failure was not significantly different between the four groups when wound infection was excluded (P = 0.156).

Most complications requiring re-operation occurred within the first two years following treatment, but reconstruction failure occurred up to 10 years after reconstruction.

Rethinking the paradigm

“Many patients undergoing mastectomy get expanders and/or implants whether or not they have radiation therapy,” says Dr. Shah. “We may need to rethink that paradigm.”

These findings indicate that radiation therapy in patients with AR results in fewer complications and reconstruction failures than radiation therapy in patients with TE/I. Yet risk of failure with TE/I can be reduced by minimizing risk of infection.

Radiation oncologists should discuss treatment options in a multidisciplinary, collaborative group with breast surgeons and plastic surgeons, ensuring plans are in place for managing reconstruction risks, says Dr. Shah.

Advertisement

Related Articles

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Lobular breast cancer cells
December 22, 2025/Cancer/Innovations
Comprehensive Lobular Breast Cancer Program Addresses Often-Misunderstood Disease

Care paths and research initiatives aim to answer unmet clinical needs

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Ad